In the course of advising multiple biopharma clients on their companion diagnostic (CDx) development programs, Precision for Medicine has identified bridging from local tests to the clinical trial assay and future CDx as a critical bottleneck. Often, assay validation requires additional mutated or wild type samples to supplement reserved tissue from trial subjects. In response, Precision has embarked on a large-scale initiative to sequence curated samples from our massive tissue archive, Project P.O.S.I.-the Precision Oncology Sequencing Initiative.
On February 22, 2022, David Parker, PhD, Senior Vice President for Diagnostics Solutions at Precision for Medicine, delivered a presentation entitled, From Biobank to CDx: Smoothing the Path to Validation at the 29th International Molecular Med Tri-Con Virtual Conference & Expo, a leading international forum for the precision medicine community. In his talk, Dr. Parker discussed how CDx development programs can be accelerated by overcoming the barriers of exhausted or insufficient clinical trial material by using pre-characterized, disease-specific specimens.
Precision for Medicine, a global leader in supplying biospecimens, lab services, and CRO services to the life sciences industries, was pleased to have Dr. Parker share his strategic insights with the TriCon audience.
Complete this simple form to access your resource.
Copyright © 2024 Precision For Medicine, Inc. All Rights Reserved.